Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
ASPC manual of preventive cardiology / / editors, Nathan D. Wong, Ezra A. Amsterdam, and Roger S. Blumenthal
| ASPC manual of preventive cardiology / / editors, Nathan D. Wong, Ezra A. Amsterdam, and Roger S. Blumenthal |
| Pubbl/distr/stampa | New York : , : demosMEDICAL, , 2015 |
| Descrizione fisica | 1 online resource (295 p.) |
| Disciplina | 616.1/05 |
| Soggetto topico | Cardiovascular system - Diseases - Prevention |
| Soggetto genere / forma | Electronic books. |
| ISBN | 1-61705-141-1 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Title; Copyright; Contents; Contributors; Foreword; Preface; Acknowledgments; Share ASPC Manual of Preventive Cardiology; Chapter 1: National Burden of Cardiovascular Disease and Associated Risk Factors; Cardiovascular Disease; Mortality and Morbidity Attributable to CVD; Prevalence and Control of Cardiovascular Risk Factors; Subclinical Atherosclerosis; Ankle-Brachial Index; Economic Costs of Cardiovascular Disease; Summary; Acknowledgments; References; Chapter 2: Cardiovascular Risk Assessment; Rationale for Contemporary CV Risk Prediction
Relative Risk Versus Absolute Cardiovascular RiskTreatment Benefit Depends on Absolute Risk Rather Than Relative Risk; Multiple, Online Risk Prediction Tools for CVD are Widely Available; Current Guideline Recommendations; Current Clinical Practice Guidelines Suggest That the Indication and Intensity of Treatment Should Be Proportional to the Absolute Risk for CVD; Novel Developments in Global CVD Risk: Considering Alternative CVD Outcomes; Novel Developments in Global CVD Risk: Considering Alternative Risk Factors; Novel Serum Markers; Novel Imaging Markers; Other Risk Markers Novel Developments in Global CVD Risk: Considering Long-Term or Lifetime RiskConclusion; References; Chapter 3: The New American Prevention Guidelines: Aligning the Guidelines for Atherosclerotic Cardiovascular Risk Reduction With the Evidence; A New Approach; Major Themes; What You Need to Know; A. Heart Healthy Nutrition and Physical Activity Behaviors; B. Recommendations from the Risk Assessment Workgroup With Those Reflecting Expert Opinion Highlighted in Italics; C. Graded Recommendations for Statin Treatment to Reduce ASCVD Risk Footnotes to this Section (from the Cholesterol Guideline Report)Statin Safety Recommendations; Footnotes to this Section (from the Cholesterol Guideline Report); Monitoring Statin Therapy; Optimizing Statin Therapy; Insufficient Response to Statin Therapy; Footnotes to this Section (from the Cholesterol Guideline Report); Conclusions; References; Chapter 4: Management of High Blood Pressure; Epidemiology of Hypertension; Definition and Classification of Hypertension; Initial Evaluation of the Patient; Thresholds for Initiating Therapy; Lifestyle Modifications; Initial Drug Therapy Goal Blood Pressure for "Uncomplicated" Hypertensive PatientsGoal Blood Pressure for Hypertensive Patients with Other High-Risk Conditions; Other Issues; References; Chapter 5: Smoking and Passive Smoking; Smoking and Cardiovascular Disease; Secondhand Smoke; Trends in Cigarette Smoking; Prevention and Reduction of Tobacco Use Among Youth; Prevention and Cessation Programs for Adults; Cessation Strategies for Individuals; Behavioral Treatments; Pharmacologic Interventions; Clinical Approaches; Conclusions; References; Chapter 6: Metabolic Syndrome; History, Prevalence, and Epidemiology Definition |
| Record Nr. | UNINA-9910463373803321 |
| New York : , : demosMEDICAL, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ASPC manual of preventive cardiology / / editors, Nathan D. Wong, Ezra A. Amsterdam, and Roger S. Blumenthal
| ASPC manual of preventive cardiology / / editors, Nathan D. Wong, Ezra A. Amsterdam, and Roger S. Blumenthal |
| Pubbl/distr/stampa | New York : , : demosMEDICAL, , 2015 |
| Descrizione fisica | 1 online resource (295 p.) |
| Disciplina | 616.1/05 |
| Soggetto topico | Cardiovascular system - Diseases - Prevention |
| ISBN | 1-61705-141-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Title; Copyright; Contents; Contributors; Foreword; Preface; Acknowledgments; Share ASPC Manual of Preventive Cardiology; Chapter 1: National Burden of Cardiovascular Disease and Associated Risk Factors; Cardiovascular Disease; Mortality and Morbidity Attributable to CVD; Prevalence and Control of Cardiovascular Risk Factors; Subclinical Atherosclerosis; Ankle-Brachial Index; Economic Costs of Cardiovascular Disease; Summary; Acknowledgments; References; Chapter 2: Cardiovascular Risk Assessment; Rationale for Contemporary CV Risk Prediction
Relative Risk Versus Absolute Cardiovascular RiskTreatment Benefit Depends on Absolute Risk Rather Than Relative Risk; Multiple, Online Risk Prediction Tools for CVD are Widely Available; Current Guideline Recommendations; Current Clinical Practice Guidelines Suggest That the Indication and Intensity of Treatment Should Be Proportional to the Absolute Risk for CVD; Novel Developments in Global CVD Risk: Considering Alternative CVD Outcomes; Novel Developments in Global CVD Risk: Considering Alternative Risk Factors; Novel Serum Markers; Novel Imaging Markers; Other Risk Markers Novel Developments in Global CVD Risk: Considering Long-Term or Lifetime RiskConclusion; References; Chapter 3: The New American Prevention Guidelines: Aligning the Guidelines for Atherosclerotic Cardiovascular Risk Reduction With the Evidence; A New Approach; Major Themes; What You Need to Know; A. Heart Healthy Nutrition and Physical Activity Behaviors; B. Recommendations from the Risk Assessment Workgroup With Those Reflecting Expert Opinion Highlighted in Italics; C. Graded Recommendations for Statin Treatment to Reduce ASCVD Risk Footnotes to this Section (from the Cholesterol Guideline Report)Statin Safety Recommendations; Footnotes to this Section (from the Cholesterol Guideline Report); Monitoring Statin Therapy; Optimizing Statin Therapy; Insufficient Response to Statin Therapy; Footnotes to this Section (from the Cholesterol Guideline Report); Conclusions; References; Chapter 4: Management of High Blood Pressure; Epidemiology of Hypertension; Definition and Classification of Hypertension; Initial Evaluation of the Patient; Thresholds for Initiating Therapy; Lifestyle Modifications; Initial Drug Therapy Goal Blood Pressure for "Uncomplicated" Hypertensive PatientsGoal Blood Pressure for Hypertensive Patients with Other High-Risk Conditions; Other Issues; References; Chapter 5: Smoking and Passive Smoking; Smoking and Cardiovascular Disease; Secondhand Smoke; Trends in Cigarette Smoking; Prevention and Reduction of Tobacco Use Among Youth; Prevention and Cessation Programs for Adults; Cessation Strategies for Individuals; Behavioral Treatments; Pharmacologic Interventions; Clinical Approaches; Conclusions; References; Chapter 6: Metabolic Syndrome; History, Prevalence, and Epidemiology Definition |
| Record Nr. | UNINA-9910787804503321 |
| New York : , : demosMEDICAL, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ASPC manual of preventive cardiology / / editors, Nathan D. Wong, Ezra A. Amsterdam, and Roger S. Blumenthal
| ASPC manual of preventive cardiology / / editors, Nathan D. Wong, Ezra A. Amsterdam, and Roger S. Blumenthal |
| Pubbl/distr/stampa | New York : , : demosMEDICAL, , 2015 |
| Descrizione fisica | 1 online resource (295 p.) |
| Disciplina | 616.1/05 |
| Soggetto topico | Cardiovascular system - Diseases - Prevention |
| ISBN | 1-61705-141-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Title; Copyright; Contents; Contributors; Foreword; Preface; Acknowledgments; Share ASPC Manual of Preventive Cardiology; Chapter 1: National Burden of Cardiovascular Disease and Associated Risk Factors; Cardiovascular Disease; Mortality and Morbidity Attributable to CVD; Prevalence and Control of Cardiovascular Risk Factors; Subclinical Atherosclerosis; Ankle-Brachial Index; Economic Costs of Cardiovascular Disease; Summary; Acknowledgments; References; Chapter 2: Cardiovascular Risk Assessment; Rationale for Contemporary CV Risk Prediction
Relative Risk Versus Absolute Cardiovascular RiskTreatment Benefit Depends on Absolute Risk Rather Than Relative Risk; Multiple, Online Risk Prediction Tools for CVD are Widely Available; Current Guideline Recommendations; Current Clinical Practice Guidelines Suggest That the Indication and Intensity of Treatment Should Be Proportional to the Absolute Risk for CVD; Novel Developments in Global CVD Risk: Considering Alternative CVD Outcomes; Novel Developments in Global CVD Risk: Considering Alternative Risk Factors; Novel Serum Markers; Novel Imaging Markers; Other Risk Markers Novel Developments in Global CVD Risk: Considering Long-Term or Lifetime RiskConclusion; References; Chapter 3: The New American Prevention Guidelines: Aligning the Guidelines for Atherosclerotic Cardiovascular Risk Reduction With the Evidence; A New Approach; Major Themes; What You Need to Know; A. Heart Healthy Nutrition and Physical Activity Behaviors; B. Recommendations from the Risk Assessment Workgroup With Those Reflecting Expert Opinion Highlighted in Italics; C. Graded Recommendations for Statin Treatment to Reduce ASCVD Risk Footnotes to this Section (from the Cholesterol Guideline Report)Statin Safety Recommendations; Footnotes to this Section (from the Cholesterol Guideline Report); Monitoring Statin Therapy; Optimizing Statin Therapy; Insufficient Response to Statin Therapy; Footnotes to this Section (from the Cholesterol Guideline Report); Conclusions; References; Chapter 4: Management of High Blood Pressure; Epidemiology of Hypertension; Definition and Classification of Hypertension; Initial Evaluation of the Patient; Thresholds for Initiating Therapy; Lifestyle Modifications; Initial Drug Therapy Goal Blood Pressure for "Uncomplicated" Hypertensive PatientsGoal Blood Pressure for Hypertensive Patients with Other High-Risk Conditions; Other Issues; References; Chapter 5: Smoking and Passive Smoking; Smoking and Cardiovascular Disease; Secondhand Smoke; Trends in Cigarette Smoking; Prevention and Reduction of Tobacco Use Among Youth; Prevention and Cessation Programs for Adults; Cessation Strategies for Individuals; Behavioral Treatments; Pharmacologic Interventions; Clinical Approaches; Conclusions; References; Chapter 6: Metabolic Syndrome; History, Prevalence, and Epidemiology Definition |
| Record Nr. | UNINA-9910821507203321 |
| New York : , : demosMEDICAL, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||